Cencora, Inc. (NYSE:COR – Get Free Report) has received an average rating of “Moderate Buy” from the eleven research firms that are covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $275.60.
A number of research analysts have issued reports on COR shares. Mizuho assumed coverage on shares of Cencora in a research report on Wednesday, December 4th. They set an “outperform” rating and a $280.00 price objective on the stock. Evercore ISI increased their price target on shares of Cencora from $250.00 to $285.00 and gave the stock an “outperform” rating in a research note on Thursday, November 7th. Leerink Partners reduced their target price on Cencora from $277.00 to $275.00 and set an “outperform” rating on the stock in a report on Monday, October 7th. StockNews.com lowered Cencora from a “strong-buy” rating to a “buy” rating in a research report on Friday, September 20th. Finally, Wells Fargo & Company reduced their target price on shares of Cencora from $249.00 to $237.00 and set an “equal weight” rating on the stock in a research report on Friday, December 13th.
Get Our Latest Research Report on COR
Insider Buying and Selling
Institutional Trading of Cencora
A number of institutional investors have recently made changes to their positions in the stock. Lake Street Advisors Group LLC boosted its holdings in Cencora by 1.3% in the third quarter. Lake Street Advisors Group LLC now owns 3,415 shares of the company’s stock worth $769,000 after purchasing an additional 43 shares during the last quarter. Financial Advocates Investment Management increased its position in Cencora by 4.7% during the second quarter. Financial Advocates Investment Management now owns 978 shares of the company’s stock valued at $220,000 after acquiring an additional 44 shares during the last quarter. Venturi Wealth Management LLC lifted its holdings in Cencora by 1.0% in the third quarter. Venturi Wealth Management LLC now owns 4,447 shares of the company’s stock valued at $1,001,000 after acquiring an additional 46 shares during the period. Prime Capital Investment Advisors LLC boosted its position in Cencora by 1.2% in the third quarter. Prime Capital Investment Advisors LLC now owns 3,768 shares of the company’s stock worth $848,000 after purchasing an additional 46 shares during the last quarter. Finally, Checchi Capital Advisers LLC grew its stake in shares of Cencora by 2.2% during the 2nd quarter. Checchi Capital Advisers LLC now owns 2,217 shares of the company’s stock valued at $499,000 after purchasing an additional 48 shares during the period. Hedge funds and other institutional investors own 97.52% of the company’s stock.
Cencora Trading Up 0.6 %
COR opened at $227.69 on Friday. The firm has a market capitalization of $44.01 billion, a price-to-earnings ratio of 30.32, a PEG ratio of 1.54 and a beta of 0.45. Cencora has a one year low of $199.82 and a one year high of $253.27. The business has a 50 day simple moving average of $239.00 and a two-hundred day simple moving average of $234.13. The company has a debt-to-equity ratio of 4.84, a current ratio of 0.88 and a quick ratio of 0.53.
Cencora Increases Dividend
The company also recently declared a quarterly dividend, which was paid on Friday, November 29th. Investors of record on Friday, November 15th were given a dividend of $0.55 per share. The ex-dividend date was Friday, November 15th. This represents a $2.20 annualized dividend and a dividend yield of 0.97%. This is an increase from Cencora’s previous quarterly dividend of $0.51. Cencora’s dividend payout ratio (DPR) is 29.29%.
Cencora Company Profile
Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.
Featured Stories
- Five stocks we like better than Cencora
- How to Buy Cheap Stocks Step by Step
- XPO Stock Gains Momentum as U.S. Trade Outlook Evolves
- Using the MarketBeat Dividend Tax Calculator
- CarMax Gets in Gear: Is Now the Time to Buy?
- When to Sell a Stock for Profit or Loss
- Qubit Combat: 2 Stocks Battle for Quantum Supremacy
Receive News & Ratings for Cencora Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cencora and related companies with MarketBeat.com's FREE daily email newsletter.